Fate Therapeutics, Inc. FATE 深 滬
等待開盤 05-22 09:30:00 美东时间
2.095
+0.255
+13.86%
華盛通- 最 高2.15
- 今 開1.79
- 成交量 494.54万股
- 最 低 1.785
- 昨 收 1.84
- 總市值 2.44亿
- 52周最高 2.465
- 市盈率 靜 --
- 換手率 4.24%
- 52周最低 0.91
- 委 比 -5.67%
- 總股本 1.17亿
- 歷史最高 121.16
- 量 比 1.50
- 振 幅 19.84%
- 歷史最低 0.6611
- 每 手 1
- 風險率 0.26%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Fate Therapeutics To Feature Data From Off-The-Shelf CAR T-Cell Programs At 2026 ASCO And EULAR Annual Meetings
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with
05-21 20:34
Fate Therapeutics Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $1.299M Beat $1.139M Estimate
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 18.75 percent increase over losses of $(0.32) per share from
05-13 20:33
Fate Therapeutics To Present Data For Its Off-The-Shelf CAR T-Cell Programs At American Society Of Gene And Cell Therapy Annual Meeting
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to
05-11 20:33
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
05-07 01:35
美股牛股 | AI“带飞”建筑巨头！STRL绩后股价狂飙逾50%，光互连概念POET单日反弹逾29%
AI“带飞”建筑巨头！STRL绩后股价狂飙逾50%，Q1营收猛增91%；光互连概念POET单日反弹逾29%>>
05-06 19:14
美股牛股 | 多重利好！Circle大涨近20%，CLARITY法案取得关键进展并获但斌买入；GBTG飙升超57%
多重利好！Circle大涨近20%，CLARITY法案取得关键进展并获但斌买入；GBTG飙升超57%，获Long Lake以63亿美元收购>>
05-05 18:24
美股大行评级 | 潜在涨幅85%！SoFi获机构升目标价至49美元；华尔街大行看涨AMD至400美元
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从28美元升至49美元；HC Wainwright & Co.：维持Fate Therapeutics"买入"评级，目标价从5美元升至7美元
05-05 11:40
Fate Therapeutics To Present Clinical Data From Its FT819 Candidate At Congress Of Clinical Rheumatology In Florida
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with
04-30 21:02
Fate Therapeutics Says Preclinical Data From Next-Gen, Off-The-Shelf CAR T-Cell Product Candidate, FT839, To Be Featured At 2026 AACR Annual Meeting
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with
04-16 21:09
Scalable Biotech Manufacturing Unlocks a $14B Market
Issued on behalf of Avaí Bio, Inc. VANCOUVER, BC, March 27, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary — The global cell therapy manufacturing market is hitting a pivotal inflecti...
03-27 21:15
